Tumor infiltrating dendritic cells (TIDCs) are thought to be potent antigen-presenting cells able to activate tumor-specific cytotoxic T lymphocytes (CTLs) or tolerogenic DCs that suppress immune reaction against tumors to escape. We have recently reported that majority of these TIDCs were DEC-205 + DCs having a cross-presenting ability of captured tumor antigens to CD8 + T cells via class I MHC (MHC-I) molecules, nevertheless, when the TIDCs expressed down-modulated costimulatory molecules, such as CD80 and CD86, they will inhibit the priming and activation of immune effectors (Immunol. Cell Biol., 91: 545-555, 2013). Here, we show that DC-precursors (preDCs) but not the established DCs become tolerogenic DCs expressing down-regulated costimulatory molecules having low responsiveness to LPS or tumor cells, when exposed to soluble factors released from the encountered ovarian tumors in the early phase of their development. However, we found that we could reduce the secretion of those soluble factors with a low, nontoxic concentration of paclitaxel (PTX) and we could stop the preDCs to be tolerogenic DCs and maintain DC functions. These findings indicate that we could prevent the induction of tolerogenic DCs from preDCs by using low, non-toxic doses of anti-cancer drugs to establish DCs that effectively elicit tumor-specific CTLs.
mor peptides obtained from tumor cells are generally presented in association with the class II MHC molecules (MHC-II) on the DCs, because epitopes from exogenously captured antigenic molecules are processed in the endosome and presented by the MHC-II, which are able to prime CD4 + T cells (6, 23). By contrast, peptide epitopes within antigenic molecules synthesized endogenously are presented by MHC-I on the DCs and can prime CD8 + CTLs if the appropriate co-stimulatory molecules are expressed on the DCs (17, 26) . It has recently been demonstrated that human CD141 + DCs (12) and mouse CD8α + DCs (4), both of which express DEC-205 (CD205) (3), have a unique capacity for "cross-presentation" (21) by which externally captured antigenic proteins can be presented by the MHC-I (22) . Therefore, DEC-205 + DCs that have captured tumor fragments containing an epitope peptide can prime tumor-specific CTLs if Anti-neoplastic chemotherapeutic agent. The antimicrotubule agent paclitaxel (PTX: Taxol), which is widely used for ovarian cancer treatment, was purchased from Bristol-Myers Squibb Co. (Shinjuku, Tokyo, Japan) and dissolved in endotoxin-free water to the appropriate concentrations.
Generation of DCs from monocytes co-cultured with
OVCAR-3 cells. DCs were obtained from peripheral blood monocytes as described previously (25) . Briefly, monocytes were freshly isolated with FicollHypaque (Amersham-Pharmacia Biotech, Uppsala, Sweden) from the peripheral blood of healthy donors, and the CD14 + monocytes were immediately separated an Easy Sep magnetic isolation kit (StemCell technologies, Vancouver, British Columbia, Canada) according to the manufacturer's instructions. Following separation, 5 × 10 5 /well CD14 + monocytes were seeded with different concentrations of OVCAR-3 cells (3 × 10 4 , 1 × 10 5 , and 3 × 10 5 / well) in 24-well plates and incubated in 1 mL complete culture medium (14) supplemented with 2 mM L-glutamine (Invitrogen), 100 units/mL penicillin (Invitrogen), 100 μg/mL streptomycin (Invitrogen), 1 mM HEPES (Invitrogen), 1 mM sodium pyruvate (Invitrogen), and 50 mM 2-mercaptoethanol (2-ME) (Invitrogen). The cells were incubated for an additional 6 days in the culture medium supplemented with 200 ng/mL GM-CSF (PeproTech, Rocky Hill, NJ) and 20 ng/mL IL-4 (Invitrogen) to obtain DCs, and 1.0 ng/mL of LPS was added to the culture medium 24 h before the end of the incubation period. This study was approved by the Review Board of Nippon Medical School, and all human participants gave written informed consent.
Quantification of cytokine production by ELISA. The culture supernatants were collected and stored at −80°C until the cytokine levels were measured. The levels of TNF-α, IL-12p40, and IL-10 were determined using the DuoSet ELISA Developmental Kit (R&D systems, Minneapolis, MN) according to the manufacturer's instructions. + DCs. Nonetheless, as demonstrated in present study, the DC-precursors (preDCs) in the peripheral blood monocytes, which will differentiate into DCs when incubated with GM-CSF and IL-4 for 6 days, could become tolerogenic DCs with down-regulated costimulatory molecules and a low responsiveness to LPS or tumor cell stimulation when co-cultured with ovarian tumor cells or their soluble factors during the early stage of DC development. However, when using the ovarian tumor cell line OVCAR-3 (8) in the presence of non-toxic concentration of paclitaxel (PTX), a known anti-cancer drug for ovarian cancer cells, we can prevent preDCs from becoming tolerogenic DCs so that they maintain DC functions. We therefore propose a new strategy for cancer treatment by using a low, nontoxic concentration of anti-cancer drugs to prevent the development of tolerogenic DCs with impaired antigenpresenting function from preDCs by reducing the ability of the tumor cells to secrete soluble factors that are responsible for inducing tolerogenic DCs.
MATERIALS AND METHODS
Cell lines. The human ovarian carcinoma cell line OVCAR-3 (HTB-161) (8) and OV-90 (CRL-11732) (13) were cultured at 37°C and 5% CO 2 in RPMI-1640 medium (Invitrogen Life Technologies, Carlsbad, CA) supplemented with 20% fetal calf serum (HyClone, Logan, UT), and 0.01 mg/mL bovine insulin (Sigma-Aldrich, St. Louis, MO) and in a 1 : 1 mixture of MCDB 105 (Sigma-Aldrich) and Medium 199 (Sigma-Aldrich) supplemented with 15% FCS (HyClone), respectively.
RESULTS

Effects of co-culturing with OVCAR-3 ovarian tumor cells on the maturation of preDCs
As shown in the Materials and Methods section, 5 × 10 5 CD14 + monocytes obtained from healthy volunteers were incubated in complete culture medium (14) containing GM-CSF (200 ng/mL) and IL-4 (20 ng/mL) for 6 days to induce CD11c + DCs. When 5 × 10 5 of the obtained DCs were incubated overnight with 1.0 ng/mL LPS, a known TLR4 ligand, they became mature DCs that expressed enhanced levels of CD80/CD86 in comparison with the stimulated cells (Fig. 1A , left and right panels). Similarly, when the DCs were co-cultured overnight with 1 × 10 5 OVCAR-3 cells, an established ovarian tumor line, they also became mature DCs that expressed enhanced levels of CD80/CD86 ( + immature DCs with decreased CD80/ CD86 expression. However, when the DCs were exposed to the OVCAR-3 cells more than 2 days after initiating the culture, they became mature DCs with increased CD80/CD86 expression in response to the OVCAR-3 tumor cells (Fig. 1C , lower panels). These findings suggest that preDCs became tolerogenic DCs with poor responses to tumor cells when they were stimulated with tumor cells, such as OVCAR-3 cells, during their early induction phase (from day 0 to day 1). We then measured the levels of various cytokines secreted from the tolerogenic DCs following stimulation with 1.0 ng/mL LPS. In comparison with normal DCs, the tolerogenic DCs that have been cocultured with 1 × 10 5 OVCAR-3 cells/well became poor producers of TNF-α or IL-12 but fair producers of IL-10 when stimulated with LPS (Fig. 1D) . These results indicate that the tolerogenic DCs lose (mAbs) to mouse IgG1κ and an isotype control and anti-human mAbs to HLA-ABC, HLA-DR, CD1a, CD11c, CD14, CD40, CD80, CD86, CD205, TLR2, TLR4, PD-1, and PD-L1 were all purchased from BD Biosciences. Cells were stained with the relevant antibody on ice for 30 min in PBS with 2% FCS and 0.01 M sodium azide (PBS-based medium), washed twice, and re-suspended in the PBSbased medium.
Blocking of PD-1 and PD-L1 molecules.
Monocytes seeded at 5 × 10 5 were co-cultured with 1 × 10 5 /well OVCAR-3 cells in the presence of 200 ng/mL GM-CSF and 20 ng/mL IL-4 together with a 10 μg/mL anti-PD-1-specific mAb (EH12.2H7) (BioLegend, San Diego, CA) and/or 10 μg/mL anti-PD-L1-specific mAb (29E.2A3) (BioLegend) for 6 days. Next, CD80/CD86 expression was analyzed by flow cytometry following stimulation with 1.0 ng/mL LPS.
Pre-treatment of CD14
+ monocytes with various concentration of PTX before generating DCs. As described above, CD14 + monocytes were separated from the PBMCs and co-cultured with OVCAR-3 cells in 24-well plates. We then added 0.04, 0.4, 4, or 40 nM of PTX to each well and incubated the cells for additional 6 days in the culture medium supplemented with same concentrations of GM-CSF and IL-4. Twenty-four h before the incubation was completed, 1.0 ng/mL LPS was added to the medium.
Growth inhibition assay of OVCAR-3 cells. Growth inhibition assay of OVCAR-3 cells was performed by incubating 1 × 10
4 OVCAR-3 cells with 0, 0.04, 0.4, 4, or 40 nM PTX in 200 μL of the culture medium for 2 days at 37°C in 5% CO 2 . The samples were cultured in 96-well flat bottom plates. The cells were then labeled for 17 h with 1 μCi/well of tritiated thymidine (3H-TdR; MP Biomedicals, Morgan, CA), harvested using an automated plate harvester (TomTech, Orange, CT), and counted in a 1,450 Micro Beta TRILUX scintillation spectrometer (Wallac, Gaithersburg, MD). The obtained data are expressed as the mean count per minute (cpm).
Statistical analysis. The results were analyzed by using non-parametrical Mann-Whitney U-test, and are presented as the mean ± standard deviations (SD). P values of < 0.05 were considered significant. and/or an anti-PD-L1-specific mAb for 6 days, most of the obtained DCs did not mature to express enhanced CD80/CD86 when stimulated with 1.0 ng/ mL LPS (Fig. 3B, upper panels) . In addition, majority of those culture supernatants did not show apparent TNF-α, IL-12p40, or IL-10 production compared with normal DCs stimulated with 1.0 ng/mL LPS (Fig. 3B, lower panels) . Therefore, interaction between PD-L1 on the OVCAR-3 cells and PD-1 on the preDCs was not the cause of the induction of tolerogenic DCs.
Effects of tumor-derived soluble factors on the induction of tolerogenic DCs
Next, we examined the requirements for direct cellto-cell interactions between the OVCAR-3 ovarian tumor cells and the preDCs to elicit tolerogenic DCs using a trans-well microplate system. As demonstrated in Fig. 4A , even in the trans-well system, which completely abrogated direct interactions between the OVCAR-3 cells and preDCs during incubation, tolerogenic DCs that could not be matured by stimulation with 1.0 ng/mL LPS were generated. Similar to our previous findings, those tolerogenic DCs did not secrete TNF-α, IL-12p40, or IL-10 when stimulated with 1.0 ng/mL LPS (Fig. 4B) . Thus, some soluble factors secreted from OVCAR-3 ovarian tumor cell line may drive preDCs to tolerogenic DCs.
Another ovarian tumor line, OV-90, also induced tolerogenic DCs from preDCs
OVCAR-3 cells secrete the known tumor-specific marker CA125 but not CEA, whereas the ovarian tumor OV-90 cells secrete CEA but not CA125 (Fig. 5A) . Thus, we examined whether the OV-90 cells can also stimulate preDCs to become tolerogenic DCs. When 5 × 10 5 monocytes were co-cultured with 1 × 10 5 /well OV-90 cells in the presence of GM-CSF and IL-4 for 6 days, the obtained DCs did not mature to express enhanced CD80/CD86 when stimulated with 1.0 ng/mL LPS (Fig. 5B , left and middle upper and lower panels). Therefore, similar to the OVCAR-3 cells, OV-90 cells can also stimulate preDCs to become tolerogenic DCs. By using a trans-well system, OV-90 cells also induced the differentiation of tolerogenic DCs from preDCs (Fig. 5B, lower right panel) , indicating that tumorspecific factors such as CA125 and CEA may not be responsible for inducing the tolerogenic DCs. Indeed, this was confirmed by blocking with anti-CA125 Ab or anti-CEA Ab (M. Shimizu and H. Takahashi, unpublished observations), and the tutheir ability to elicit cellular immunity mediated by cytotoxic T lymphocytes (CTLs) against the encountered tumor cells.
Analysis of surface markers on the tolerogenic DCs
We next examined the expression of various surface molecules on the tolerogenic DCs induced from preDCs by co-culturing with OVCAR-3 cells. The normally induced DCs and the obtained tolerogenic DCs expressed similar levels of DC-related markers, such as CD11c and CD1a, and class I MHC molecules (MHC-I), such as HLA-ABC, while the expression of class II MHC molecules (MHC-II), like HLA-DR was slightly decreased on the tolerogenic DCs ( Fig. 2A) . Although DEC-205 (CD205) expression was enhanced on the tolerogenic DCs, the surface expression of the co-stimulation molecules CD80, CD86 and CD40, were significantly downregulated (Fig. 2B) . Additionally, the expression of TLR2 and TLR4 was slightly up-regulated for both un-stimulated and LPS-stimulated tolerogenic DCs (Fig. 2C) . These results imply that the tumor cellmediated tolerogenic DCs became DEC-205 + enhanced DCs that may have the ability to cross-present captured tumor antigens associated with MHC-I to antigen-specific CD8 + CTLs, but they may fail to prime the CTLs because of their down-modulated co-stimulatory molecules.
Effects of PD-1 and/or PD-L1-specific mAb treatment on the induction of tolerogenic DCs
Our current findings showed that the preDCs became tolerogenic DCs with decreased levels of costimulatory molecules following stimulation with OVCAR-3 cells during their early induction phase. To confirm the possibility that programmed cell death protein-1 ligand-1 (PD-L1) molecules on the OVCAR-3 cells were responsible for the establishment of tolerogenic DCs, based on the recent report (7, 10), the expression level of the PD-1 (programmed cell death protein-1) and PD-L1 molecules on OVCAR-3 cells, preDCs, and established DCs were examined. Although both PD-L1 and PD-1 were expressed on the CD14 + DC precursor cells and the established DCs, PD-1 expression was not found on the OVCAR-3 cells (Fig. 3A) . Thus, we performed the blocking experiments of PD-L1 and/ or PD-1 with each specific antibody to determine whether such blocking may abrogate the induction of tolerogenic DCs. When 5 × 10 5 monocytes were co-cultured with 1 × 10 5 /well OVCAR-3 cells in the presence of GM-CSF and IL-4 with either an anti-PD-1-specific mAb Fig. 2 Analysis of surface markers on the tolerogenic DCs. A, The expression of DC-related markers, CD11c, CD1a, class I MHC molecules (HLA-ABC), and class II MHC molecules (HLA-DR) on the tolerogenic DCs (lower panels) was examined to compare normal DCs (upper panels). B, The expression of DC-related DEC-205, and co-stimulatory molecules, such as CD80, CD86, and CD40 on the tolerogenic DCs (lower panels) was examined to compare normal DCs (upper panels). C, The expression of TLR ligands, such as TLR2 and TLR4, on the tolerogenic DCs (lower panels) and normal DCs (upper panels) was analyzed for both unstimulated and LPS-stimulated ones.
mor-cell derived factor(s) that elicits tolerogenic DCs remains unknown. However, if we can reduce the amount of tumor-derived tolerogenic factors, the emergence of tolerogenic DCs can be prevented, and tumor-specific immunity can be obtained.
Nontoxic low dose of PTX prevented tolerogenic DC induction from preDCs
One way to reduce the secretion of tumor-derived soluble factors is to inhibit the production and secretion ability of the tumor cells. Therefore, the OVCAR-3 cells were incubated with various doses of PTX. As demonstrate in Fig. 6A , the amount of CA125 secreted from OVCAR-3 cells was inhibited when exposed to PTX concentrations higher than 4 nM. We found that 40 nM of PTX was toxic to the OVCAR-3 cells, and cell growth was completely inhibited when 40 nM of PTX was added for 24 h (Fig. 6B) . In addition, 40 nM of PTX was toxic for preDCs and prevented them from becoming established DCs (Fig. 6C) . However, 4 nM of PTX did not show any toxicity /well OVCAR-3 cells in the presence of GM-CSF and IL-4 together with either anti-PD-1-specific mAb and/or anti-PD-L1-specific mAb for 6 days and the expression of CD80/CD86 (upper panels) and cytokine production (lower panels) were examined when stimulated with 1.0 ng/mL LPS.
as LPS. Nevertheless, as demonstrated in the present study, we showed that preDCs became tolerogenic DCs with poor responses to tumor cells when they were co-cultured with the tumor cells, such as OVCAR-3 cells, in the initial phase of the induction (from day 0 to 1) but not in the progressed or established phase of induction (from day 2 to 5). The preDCs did not require direct cell-to-cell interaction with tumor cells to become tolerogenic DCs, and incubation with a mixture of tumor-derived soluble factors was sufficient to induce tolerization. This result was compatible with our recent findings (9) in that hepatoma cell-derived soluble factors containing alpha-fetoprotein (AFP), vascular endothelial growth factor (VEGF), and transforming growth factor (TGF)-β caused DCs to down-regulate the expression of co-stimulatory molecules as long as the preDCs were incubated with those tumor-derived soluble factors. The tolerogenic DCs could not be stimulated by brief exposure to tumor antigens expressed on the tumor cells or by TLR ligands such as LPS, and against the OVCAR-3 cells or the preDCs. Thus, 5 × 10 5 monocytes were co-cultured with 1 × 10 5 / well OVCAR-3 cells in the presence of GM-CSF and IL-4 together with 4 nM PTX for 6 days, and the DC response to 1.0 nM LPS was not suppressed (Fig. 6D) . The LPS-stimulated DCs that were established in the presence of 4 nM PTX secreted augmented amounts of IL-12p40 (Fig. 6E) . These findings strongly indicate that a low, nontoxic dose of PTX can inhibit the differentiation of tolerogenic DCs from preDCs and preserves the DC response to LPS stimulation.
DISCUSSION
CD11c
+ immature DCs can be induced from CD14 + peripheral blood monocytes incubated in media containing GM-CSF and IL-4 for 6 days, and they can then be matured to express enhanced levels of costimulatory molecules, such as CD40, CD80, and CD86, by a brief exposure to either tumor cells bearing tumor antigens or specific TLR stimuli such + impaired tolerogenic DCs with downmodulated co-stimulatory molecules that will paralyze the CTL-based anti-tumor immune response (11) . To prevent tumor growth, these tolerogenic DCs with a negative influence on the neighboring immune system should be deleted or altered. Indeed, Scarlet et al. recently showed that the eradication of these tolerogenic DCs from the tumor-bearing mice resulted in a regression in the tumor mass (19) . As we have shown here, we could also prevent the they became poor producers of TNF-α and IL-12. The tolerogenic DCs lost their ability to elicit cellular immunity such as CTLs against the encountered tumor cells, although they expressed comparable levels of class I MHC and enhanced levels of DEC-205 molecules. DEC-205 + DCs can cross-present (5) captured antigens via their MHC-I molecules to prime and activate tumor-specific class I MHC molecule-restricted CD8 + CTLs if they express an appropriate number of co-stimulatory molecules. However, tolerogenic DCs may fail to induce functional CTLs and instead can permit or facilitate tumor escape. The mechanism by which tumor cells drive neighboring preDCs to become cross-reactive antigen-presenting cells needs to be investigated. However, tumor-derived factors seem to stimulate the antigenpresenting cells to initiate an immune response through MHC-I via cross-presentation. Nevertheless, the initial signaling cannot activate the antigen-specific effector CTLs because of down-modulated co- emergence of the tolerogenic DCs by using a low, nontoxic amount of anti-cancer drugs during the initiation steps together with an approach to drive + preDCs into functional DCs with appropriate co-stimulatory molecule expression.
